NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Talkspace (Nasdaq: TALK), a leading behavioral healthcare company, released early findings of a landmark study in the delivery of asynchronous psychotherapy, which enables the ability to text with licensed therapists, during the onset of the COVID-19 pandemic.
In March of 2020, researchers from Talkspace and leading academic centers recruited healthcare workers (HCWs) from major hospitals across the United States who were experiencing anxiety or depression as they cared for COVID-19 patients during the initial surge. Participants could send unlimited text messages to their therapists and would receive counseling in the form of text messages back from their respective therapists. The population included physicians, nurses at several levels, residents in training, and a small number of nonmedical sanitation workers.
Drawing on anonymized data from 601 HCWs across the United States for a relatively brief period of one month, key findings include:
Additionally, researchers analyzed an expanded subset of subject data (N=820) by leveraging machine learning capabilities called Natural Language Processing (NLP), the ability of a computer to anonymously and securely analyze what was written. Within this subset, researchers wanted to understand more specifically what brought the participants to treatment and how HCWs were engaging with their assigned therapist through the digital app.
Key findings in this controlled group include:
“Message-based care is a promising ‘lifeline’ during chaotic times and for individuals with chaotic schedules. While the uncertainty of COVID may be waning, the lives of healthcare workers and many others are no less challenging,” said Derrick Hull, PhD, Research Director, Talkspace, who leads a growing body of research with more than 23 academic publications on messaging therapy.
“To say that the healthcare industry was rocked to its core is an understatement, and no one knows that better than the physicians and nurses treating patients, trying to contain a pandemic, with dwindling space and resources--all while keeping themselves and their families safe from harm,” said Dr. Jon Cohen, CEO of Talkspace.
“The implications of our study show that one way to alleviate the ongoing distress and disproportionate anxiety and burnout presenting in healthcare workers is by availing a clinically-backed digital delivery system to provide real-time support at the moments where stress may be triggered,” said Cohen.
About Talkspace
Talkspace (NASDAQ: TALK) is a leading virtual behavioral healthcare company committed to helping people lead healthier, happier lives through access to high-quality mental healthcare. At Talkspace, we believe that mental healthcare is core to overall health and should be available to everyone.
Talkspace pioneered the ability to text with a licensed therapist from anywhere and now offers a comprehensive suite of mental health services from self-guided products to individual and couples therapy, in addition to psychiatric treatment and medication management. With Talkspace’s core psychotherapy offering, members are matched with one of thousands of licensed providers across all 50 states and can choose from a variety of subscription plans including live video, text or audio chat sessions and/or unlimited, asynchronous text messaging.
All care offered at Talkspace is delivered through an easy-to-use, fully-encrypted web and mobile platform that meets HIPAA, federal, and state regulatory requirements. Talkspace covered approximately 86 million lives at September 30, 2022, through partnerships with insurance and employee assistance programs or other network behavioral health paid benefit programs.
For more information, visit www.talkspace.com.
For Media:
SKDK
John Kim
310-997-5963
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$3.04 |
Daily Change: | -0.13 -4.10 |
Daily Volume: | 2,048,192 |
Market Cap: | US$511.360M |
October 29, 2024 September 04, 2024 August 06, 2024 July 24, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB